Literature DB >> 3025156

The antiviral activity against herpes simplex virus of the triterpenoid compounds carbenoxolone sodium and cicloxolone sodium.

D J Dargan, J H Subak-Sharpe.   

Abstract

Dose-response experiments show that the presence of 300 microM cicloxolone sodium (CCX) or 500 microM carbenoxolone sodium (CBX) during the HSV replication cycle reduced the infectious virus yield by 10,000- to 100,000-fold: CCX is the more potent anti-herpes agent. HSV-2 replication was consistently more severely restricted by either drug than was that of HSV-1. The ED50 values obtained for either drug against HSV-1 or HSV-2 correlate well with data from dose-response curves. CCX, and to a lesser extent CBX, can be cytotoxic but the degree of cytotoxicity varies between cell lines and is also affected by the physiological state of the cells. Triterpenoid drugs exhibit some activity against virus particles in suspension but the effect is small and contributes little to the overall antiviral effect. The drugs appear to be active throughout the replication cycle. In contrast to all other anti-herpesvirus agents in clinical use the triterpenoid compounds do not appear to act directly to block virus DNA synthesis. HSV mutants resistant to ACG and PAA, or lacking a thymidine kinase gene, appear as sensitive as wild-type virus to CCX inhibition. HSV growth in the presence of the drugs resulted in a lower number of assembled virus particles but reduced to a much greater extent the infectious virus yield: thus the progeny virus quality is greatly diminished. Thermolability of progeny virus correlated well with this diminution of quality in increasing CCX concentration. SDS PAGE analysis of the structural proteins of virus particles made in cells treated with 300 microM CCX revealed numerous differences in the relative intensities of protein bands, which is in keeping with the changed quality of the drug-produced virus. SDS PAGE analysis of the polypeptides induced in drug treated infected cells revealed two effects; some polypeptides were synthesised in reduced amounts and the nuclear/cytoplasmic distribution of certain proteins was affected. Post-translational processing by glycosylation and sulphation of both cellular and HSV induced proteins was strongly inhibited by the triterpenoid drugs, while phosphorylation of only a few polypeptides appeared to be affected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025156     DOI: 10.1093/jac/18.supplement_b.185

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Effect of the extracts from Glycyrrhiza uralensis Fisch on the growth characteristics of human cell lines: Anti-tumor and immune activation activities.

Authors:  W T Chung; S H Lee; J D Kim; N S Sung; B Hwang; S Y Lee; C Y Yu; H Y Lee
Journal:  Cytotechnology       Date:  2001-09       Impact factor: 2.058

2.  Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo.

Authors:  Mark L Schultz; Luis Tecedor; Elena Lysenko; Shyam Ramachandran; Colleen S Stein; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2018-04-13       Impact factor: 7.046

3.  Antiviral activity of Carbenoxolone disodium against dengue virus infection.

Authors:  Jieying Pu; Li He; Heping Xie; Siyu Wu; Yuye Li; Ping Zhang; Zhicong Yang; Xi Huang
Journal:  J Med Virol       Date:  2016-12-23       Impact factor: 2.327

Review 4.  Natural Products and Their Derivatives against Human Herpesvirus Infection.

Authors:  Chattarin Ruchawapol; Man Yuan; Si-Min Wang; Wen-Wei Fu; Hong-Xi Xu
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

Review 5.  Research Progress on the Antiviral Activity of Glycyrrhizin and its Derivatives in Liquorice.

Authors:  Changchao Huan; Yao Xu; Wei Zhang; Tingting Guo; Haochun Pan; Song Gao
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

6.  Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds.

Authors:  Louis K S Darko; Emmanuel Broni; Dominic S Y Amuzu; Michael D Wilson; Christian S Parry; Samuel K Kwofie
Journal:  Biomedicines       Date:  2021-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.